Discovery Tools (Healthcare) · San Francisco, CA · Founded 2012 · Privately Held (backing)
Developer of a bench-top primary cell control system designed to advance immunotherapy research and manufacturing, empowering scientists with better tools for cell maintenance, expansion, and control. Xcell Biosciences is based in San Francisco, CA and was founded in 2012. Its last reported valuation was $65.5 million in Sep 2021. It has raised $60.4 million across 3 recorded rounds; the latest was a $27.5 million later-stage round in Dec 2024.
Last reported valuation
$65.5M
Oct 2026
Priced at
—
Total raised
$60.4M
Last round
Later Stage VC
Dec 2024
No prints on record
No secondary trades in Xcell Biosciences shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Xcell Biosciences with a free account
·The complete investor list: 21 names
·Watch Xcell Biosciences: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Xcell Biosciences stock.
